Drugs / TER-2013

Trials 1 · a red edge is where a trial was stopped

2026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07109726 Sep 2025 → Dec 2028 expected breast cancer, cervical cancer, endometrial cancer, esophageal squamous cell carcinoma +3 Terremoto Biosciences Inc. Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TER-2013 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07109726
Route Oral Oral Capsules” NCT07109726